CN102631517B - Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN102631517B CN102631517B CN2012101368863A CN201210136886A CN102631517B CN 102631517 B CN102631517 B CN 102631517B CN 2012101368863 A CN2012101368863 A CN 2012101368863A CN 201210136886 A CN201210136886 A CN 201210136886A CN 102631517 B CN102631517 B CN 102631517B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- add
- medicine composition
- traditional chinese
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 6
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 claims description 45
- 230000036407 pain Effects 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000004821 distillation Methods 0.000 claims description 24
- 241000218176 Corydalis Species 0.000 claims description 18
- 239000009670 cang er zi wan Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 8
- 206010058019 Cancer Pain Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 2
- 241000830532 Corydalis yanhusuo Species 0.000 abstract 1
- 241001251949 Xanthium sibiricum Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000001256 steam distillation Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- -1 and 2.5 parts Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition with an analgesic effect and a preparation method of the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared by adopting ways of water decoction, steam distillation and the like to extract active ingredients from bulk drugs such as Corydalis yanhusuo, Radix Paeoniae Rubra, Herba Asari, Venenum Bufonis, Xanthium sibiricum fruit, Glycyrriza uralensis and the like according to different properties of the drugs, and prepare into capsules, tablets, granulas and pills. The traditional Chinese medicine composition provided by the invention has the effects of promoting qi and activating blood, warming and activating meridian, clearing away heat and removing toxicity, and inducing resuscitation, and is mainly used for curing mild and moderate cancer pain caused by a lung cancer, a gastric cancer, a liver cancer and the like.
Description
Technical field
The present invention relates to a kind of the have Chinese medicine composition of analgesic effect and the preparation method of said composition, particularly a kind of Chinese medicine composition for the treatment of the cancer pain and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Cancer pain refers to the pain due to cancer, cancer related pathologies and anticancer therapy, is often chronic pain, is the common symptom of cancer patient.IASP (IASP) to the definition of pain is: impression during pain on a kind of undesirable sensation and emotion is accompanied by existing or potential tissue injury.Pain is often subjective, and everyone has just learned to express the vocabulary of pain in the getting up early of life by the experience of damage.Be that pain is often a kind of subjective feeling, be subject to the impact of environment and emotion, and be not only a kind of simple physiologic response.World's pain conference in 2002 gives the theory that pain is new, thinks that pain is a kind of disease, and is not only a kind of symptom; Pain has been listed in the fifth-largest vital sign of human body; All pain is all pernicious, never has optimum pain; Drug therapy is topmost part in pain therapy; Targeting, dose-effect relationship are linear to following pain therapy medicine more, action time is more lasting.
Cancer accounts for first of the current world population cause of the death.The middles and advanced stage that belong to while going to a doctor due to cancer patient, therefore, pain becomes a common sympton, directly affects patient's quality of life more.According to estimates, the existing cancer patient in the whole world approximately 1,400 ten thousand, wherein 30%～60% with pain in various degree, and most patients with advanced cancer are just experiencing the torment of cancer pain, and the nearly half patient does not obtain satisfied alleviation.The existing cancer patient of China approximately 2,000,000, pain incidence rate 40%～50%, wherein 25% patient does not obtain medical treatment, in, severe pain accounts for 20%.Therefore, control cancerous pain and be put into one of 4 emphasis of World Health Organization's cancer Comprehensive Control planning.Therefore, the alleviation cancerous pain is very necessary.
Cancerous pain is the pain that the cancer patient produces under various harmful factors stimulate, and makes the patient very painful, affects carrying out smoothly of effective antitumor plan.Due to aggravation and the intense stimulus of pain, directly affect patient's appetite, sleep, psychologic status and therapeutic effect, and having a strong impact on patient's life quality, be that the cancer patient loses treatment confidence and one of the major reason of desire of surviving.Cancer pain is as the common sympton of tumor, and its cause of disease directly and Tumor-assaciated.On treatment pain, Chinese and western medicine is fully different, and thinking is different.Doctor trained in Western medicine is all generally the neural pain relieving of anesthesia, the local anesthesia of pain is got up, allow the imperceptible pain of patient, in fact pain also exists, and has just anaesthetized nerve, has alleviated misery, alleviated symptom, the state of an illness also, in development, does not play any therapeutic effect, and excessive anesthetics has caused destruction to gastrointestinal function and hepatic and renal function.
Chinese medicine is obtaining significant progress aspect the treatment of cancer pain.Cancerous pain is very common in tumor patient, and the reason of its generation has multiple, as tumor is directly invaded or pressuring nerve; The tumor ramp is increased the peplos tension force of organ; The compressing of tumor makes the histoorgan ischemic necrosis; Tumor is broken or the impact of ulcer and some psychological factor etc.Control pain, can strengthen the confidence of patient to successive treatment timely and effectively, for essential condition is created in the treatment of protopathy.For late tumor patient, control pain can make its life quality be improved.For this reason, the treatment of control cancerous pain is listed in the emphasis planning of World Health Organization (WHO).Motherland's medical science is thought, although tumor is local patholoic change, yet, " strong people is without long-pending, and empty people has it ", the internal organs weakness, stagnation of QI-blood is the important pathologic basis of cancer.Qi depression to blood stasis, venation is obstructed, and stagnation of QI and blood may bring about pain, therefore to the suitable vital energy regualting and blood circulation-promoting of the treatment of cancerous pain, removing obstruction in the collateral to relieve pain.This Chinese medicine composition forms Chinese medicine compound by Rhizoma Corydalis, Radix Paeoniae Rubra, Rhizoma Cyperi, Herba Asari, Venenum Bufonis, the Rhizoma Pinelliae, Fructus Xanthii, Radix Glycyrrhizae etc., has the effect of promoting flow of QI and blood, promoting the flow of QI in the collateral by warming the meridian, heat-clearing and toxic substances removing, the refreshment of having one's ideas straightened out.The theory that meets the Chinese traditional treatment cancer, be applicable to spend the patient among cancerous pain.
Summary of the invention
One object of the present invention is to provide a kind of effect with promoting flow of QI and blood, removing obstruction in the collateral to relieve pain, and light, the moderate cancerous pain caused for pulmonary carcinoma, gastric cancer, hepatocarcinoma etc. belongs to the Chinese medicine composition of syndrome of qi stagnation and blood stasis;
Another object of the present invention is to provide the preparation method of above-mentioned Chinese medicine composition.
The object of the present invention is achieved like this, according to the Chinese medicine and pharmacy theory, utilizes the property of medicine of medical herbs uniqueness, adopts Rhizoma Corydalis, Radix Paeoniae Rubra, Rhizoma Cyperi, Herba Asari, Venenum Bufonis, the Rhizoma Pinelliae, Fructus Xanthii, Radix Glycyrrhizae according to certain compatibility requirement, through special process, processes.
Crude drug composition and the proportioning of preparation Chinese medicine composition of the present invention are as follows:
Rhizoma Corydalis 400～600g, Radix Paeoniae Rubra 400～600g, Rhizoma Cyperi 200～400g, Herba Asari 200～400g, Venenum Bufonis 3～7g, the Rhizoma Pinelliae 100～200g, Fructus Xanthii 200～400g, Radix Glycyrrhizae 100～200g.
The crude drug of Chinese medicine composition of the present invention forms best proportioning for (by weight):
Rhizoma Corydalis 500g, Radix Paeoniae Rubra 500g, Rhizoma Cyperi 300g, Herba Asari 300g, Venenum Bufonis 5g, Rhizoma Pinelliae 150g, Fructus Xanthii 300g, Radix Glycyrrhizae 150g.
Medicine of the present invention can be in the middle of following dosage form granule, tablet, capsule, pill a kind of.
Medicine of the present invention can adopt the preparation of following method: gets Rhizoma Cyperi, Herba Asari, Fructus Xanthii and adds 4～8 times of water gagings, add thermal distillation 3～5 hours, collect volatile oil, add 2～4 times of amount betacyclodextrins and grind 2 hours, and drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, the Rhizoma Pinelliae, Radix Glycyrrhizae merge, and add 6～10 times of water gagings and decoct 1～3 time, each 1～3 hour, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 50～70% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add the conventional adjuvant of pharmaceutics, makes required dosage form, obtains.
The preparation technology of medicine of the present invention can be: gets Rhizoma Cyperi, Herba Asari, Fructus Xanthii and adds 6 times of water gagings, add thermal distillation 4 hours, collect volatile oil, add 3 times of amount betacyclodextrins and grind 2 hours, and drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 8 times of water gagings and decoct 2 times, each 2 hours, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 60% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add the conventional adjuvant of pharmaceutics, makes required dosage form, obtains.
The application of light, the moderate cancerous pain that Chinese medicine composition of the present invention mainly causes in treatment pulmonary carcinoma, gastric cancer, hepatocarcinoma etc. in belonging to syndrome of qi stagnation and blood stasis.
Following experimental example, by light, the curative effect that the moderate cancerous pain belongs to syndrome of qi stagnation and blood stasis of observing that this traditional Chinese medicine composition for treating pulmonary carcinoma, gastric cancer, hepatocarcinoma etc. cause, further illustrates the medical application of medicine of the present invention.
Use potentiation in order to understand its prescription 5, this research adopts animal Blood stasis test model, observes the impact of Chinese medicine composition of the present invention on the animal pharmacology effect.
The impact of a pair of mice analgesic activity of experimental example
Experimental animal: the white mice of Kunming kind, body weight 18～22 grams, male and female dual-purpose.
Writhing method: utilize the acetic acid induced pain, make mice produce writhing response, the analgesic activity of checking this product.Get 40 of Kunming mouses, be divided at random 4 groups, every group 10, the water matched group, this product Chinese medicine composition group low dose, middle dosage, heavy dose of gastric infusion respectively, administration is after 30 minutes, lumbar injection 5% acetum (0.2mg/20g), observe 10 minutes endogenous cause of ill pain of every mice and cause time and the number of times of writhing, the results are shown in Table 1.
The analgesic activity (writhing method) of table 1 this product to mice
Annotate: with the water matched group, compare: * P<0.05.
Above-mentioned test data shows, each dosage group writhing of this product obviously extends incubation period, and administration is respectively organized the writhing number of times and obviously is less than the prompting of water matched group result of the test: this product analgesic activity is obvious, and the therapeutic effect of the medicine of two kinds of preparation method systems is close.
Experimental example two present compositions are on the hemorheological impact of rat experiment Blood stasis
1, given the test agent: medicine group of the present invention; Radix Salviae Miltiorrhizae Injection (1.5g/ml); Adrenalin hydrochloride injection (1mg/ml), heparin sodium powder (150,000 units/gram); Sodium citrate.
2, instrument: rotation cartridge type Blood rheology measurement, erythrocyte electrophoresis instrument, platelet adhesion instrument.
3, animal: SD kind rat, male and female half and half, body weight (300 ± 30) g.
4, test method and result
By weigh labelling be divided at random 4 groups of 40 rats, 10 every group, be respectively: blank group (20ml/kgd tap water); Blood stasis model group (20ml/kgd); Radix Salviae Miltiorrhizae positive controls (2.8g/kgd); This Chinese medicine composition group (6.0g crude drug/kgd), except blank and model group, all ig administrations in continuous 7 days.Except the blank group, all the other each groups all copy the Blood stasis model.
Model copy: in the 7th day, sc adrenalin hydrochloride 8ug/kg2 time, midfeather 4 hours, between double injection, immerse rat in frozen water 5 minutes, after disposal, stops eating.In the 8th day, with urethane (20%) intraperitoneal anesthesia (3ml/kg), the carotid artery intubate was got blood 4.2ml, and wherein 3ml injects anticoagulant heparin pipe (concentration 1.39 * 10
-2mmol/L blood), 1.2ml Induced By Na-citrate Injection Into anticoagulant tube (concentration 3.8%, test tube is silication in advance).
Heparin anti-coagulating is used for measuring:
1. the high viscosity (η that cuts of whole blood
hmPas), the low viscosity (η that cuts of whole blood
lmPas): rotating cylinder viscometer is measured, high shear rate 200s
-1, low shear rate 40s
-1.
2. erythrocyte electrophoretic time (EPSs): self blood plasma dilution, erythrocyte electrophoresis instrument are measured, and under the microscope that the chessboard scale is housed, survey erythrocyte and come and go to the left and right two lattice required times, are erythrocyte electrophoretic time.
The sodium citrate anticoagulation is used for measuring platelet adhesion rate (glass bead method): anticoagulation 1ml is placed in 5ml long-neck ball vial, be placed on the platelet adhesion instrument, to take off after 5rpm rotating speed rotation 15min, before and after rotating, anticoagulation adds platelet diluent (1% ammonium acetate solution), measure and adhere to front and back, platelet count, calculate adhesion rate (PT).
Result: this Chinese medicine composition affects experimental result in Table 2 to hemorheologic parameters.
The impact (x ± s) of table 2 compositions on hemorheologic parameters
Annotate: model group and normal group compare:
*p<0.05; Medication group and model group compare:
△p<0.05.
Result of the test shows: this Chinese medicine composition can significantly reduce the high shear viscosity of whole blood, the low shear viscosity of whole blood; Significantly reduce platelet adhesion rate, shorten electrophoresis time.Play obvious function of promoting blood circulation to disperse blood clots.
The specific embodiment
Below with specific embodiment, illustrate again, but following embodiment only for being described, does not limit the present invention in the present invention.
Embodiment 1:
Prescription: Rhizoma Corydalis 400g, Radix Paeoniae Rubra 400g, Rhizoma Cyperi 200g, Herba Asari 200g, Venenum Bufonis 3g, Rhizoma Pinelliae 100g, Fructus Xanthii 200g, Radix Glycyrrhizae 100g.
Method for making: get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 6 times of water gagings, add thermal distillation 4 hours, collect volatile oil, add 3 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 8 times of water gagings and decoct 2 times, each 2 hours, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 60% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, get 1 part of mixing fine powders, 4 parts of sucrose, and 2.5 parts, dextrin, mix, and granulates, and 60～70 ℃ of dryings, make 1000g.
Embodiment 2:
Prescription: Rhizoma Corydalis 500g, Radix Paeoniae Rubra 500g, Rhizoma Cyperi 300g, Herba Asari 300g, Venenum Bufonis 5g, Rhizoma Pinelliae 150g, Fructus Xanthii 300g, Radix Glycyrrhizae 150g.
Method for making: get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 8 times of water gagings, add thermal distillation 3 hours, collect volatile oil, add 4 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 6 times of water gagings and decoct 3 times, each 1 hour, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 50% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add starch to 360g, and mix homogeneously, make 1000 of capsules.
Embodiment 3:
Prescription: Rhizoma Corydalis 600g, Radix Paeoniae Rubra 600g, Rhizoma Cyperi 400g, Herba Asari 400g, Venenum Bufonis 7g, Rhizoma Pinelliae 200g, Fructus Xanthii 400g, Radix Glycyrrhizae 200g.
Method for making: get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 4 times of water gagings, add thermal distillation 5 hours, collect volatile oil, add 2 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 10 times of water gagings and decoct 1 time, each 3 hours, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 70% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add microcrystalline Cellulose appropriate, adds starch to 450g, mix homogeneously, and granulation, be pressed into 1000, tablet, and film coating, obtain.
Embodiment 4:
Prescription: Rhizoma Corydalis 600g, Radix Paeoniae Rubra 600g, Rhizoma Cyperi 400g, Herba Asari 400g, Venenum Bufonis 7g, Rhizoma Pinelliae 200g, Fructus Xanthii 400g, Radix Glycyrrhizae 200g.
Method for making: get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 6 times of water gagings, add thermal distillation 4 hours, collect volatile oil, add 3 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 6 times of water gagings and decoct 2 times, each 2 hours, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 70% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, abundant mix homogeneously, add carboxymethylstach sodium and microcrystalline Cellulose is appropriate, mixes, and take water as binding agent, and the pill bar, be pressed into ball, obtains.
Embodiment 5:
Get the made capsule of embodiment 2 and treat 50 routine cancer pain patients (wherein pulmonary carcinoma 18 examples, hepatocarcinoma 20 examples, gastric cancer 12 examples).Therapeutic scheme: oral, one time 3, three times on the one.The rear observation of taking medicine, pain alleviates obvious 29 examples, produce effects 15 examples, invalid 6 examples, total effective rate reaches 88%.
Claims (2)
1. the Chinese medicine composition with analgesic effect is characterized in that this Chinese medicine composition made by following raw material medicaments:
Rhizoma Corydalis 400～600g, Radix Paeoniae Rubra 400～600g, Rhizoma Cyperi 200～400g, Herba Asari 200～400g, Venenum Bufonis 3～7g, the Rhizoma Pinelliae 100～200g, Fructus Xanthii 200～400g, Radix Glycyrrhizae 100～200g;
The preparation method of this Chinese medicine composition is as follows:
Get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 4～8 times of water gagings, add thermal distillation 3～5 hours, collect volatile oil, add 2～4 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, the Rhizoma Pinelliae, Radix Glycyrrhizae merge, and add 6～10 times of water gagings and decoct 1～3 time, each 1～3 hour, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 50～70% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add the conventional adjuvant of pharmaceutics, makes required dosage form, obtains.
2. the Chinese medicine composition with analgesic effect according to claim 1 is characterized in that said composition made by following raw material medicaments:
Rhizoma Corydalis 500g, Radix Paeoniae Rubra 500g, Rhizoma Cyperi 300g, Herba Asari 300g, Venenum Bufonis 5g, Rhizoma Pinelliae 150g, Fructus Xanthii 300g, Radix Glycyrrhizae 150g;
The preparation method of this Chinese medicine composition is as follows:
Get Rhizoma Cyperi, Herba Asari, Fructus Xanthii and add 6 times of water gagings, add thermal distillation 4 hours, collect volatile oil, add 3 times of amount betacyclodextrins and grind 2 hours, drying, standby, the another device of the aqueous solution after distillation is collected; Medicinal residues and Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Glycyrrhizae merge, and add 8 times of water gagings and decoct 2 times, each 2 hours, collecting decoction and above-mentioned distillation rear solution, filter, being evaporated to 60 ℃ of mensuration relative densities is 1.05～1.10, adds ethanol and makes to reach 60% containing the alcohol amount, standing, filter, filtrate recycling ethanol, continuing to be concentrated into 60 ℃ of mensuration relative densities is 1.25～1.35, drying under reduced pressure, standby; Above-mentioned two dry things are mixed, pulverize, add the Venenum Bufonis fine powder, fully mix homogeneously, add the conventional adjuvant of pharmaceutics, makes required dosage form, obtains.
3. the Chinese medicine composition with analgesic effect according to claim 1 and 2, is characterized in that said composition can be made into any in granule, tablet, capsule, pill.
4. the application of the described Chinese medicine composition with analgesic effect of claim 1 or 2 in the medicine of light, the moderate cancerous pain caused for the preparation for the treatment of pulmonary carcinoma, gastric cancer, hepatocarcinoma etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101368863A CN102631517B (en) | 2012-05-07 | 2012-05-07 | Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101368863A CN102631517B (en) | 2012-05-07 | 2012-05-07 | Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631517A CN102631517A (en) | 2012-08-15 |
| CN102631517B true CN102631517B (en) | 2013-12-11 |
Family
ID=46616197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101368863A Active CN102631517B (en) | 2012-05-07 | 2012-05-07 | Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631517B (en) |
-
2012
- 2012-05-07 CN CN2012101368863A patent/CN102631517B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 周晓艳，等.中医药外治癌性疼痛的研究进展.《中医药导报》.2007,第13卷(第3期),第85-87页. * |
| 白桦,等.中药外用缓解癌性疼痛的研究现状与思路.《中医外治杂志》.2009,第18卷(第1期),第46-48页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631517A (en) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352608B (en) | A kind of benefiting QI for activating blood circulation, hard masses softening and resolving, the Chinese medicine and preparation method thereof of removing toxic substances pain relieving | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN106236854A (en) | The Chinese medicine composition of a kind for the treatment of of arthritis and application thereof | |
| CN105287812B (en) | A kind of medical composition and its use for treating irritable bowel syndrome | |
| CN101129971B (en) | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same | |
| CN1931277B (en) | Osteoarthrosis treating Chinese medicine composition and its preparation process | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN111437338A (en) | Application of traditional Chinese medicine composition in treating skin diseases | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN103977370A (en) | Pharmaceutical composition with effect of inducing diuresis to alleviate edema | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN102631517B (en) | Traditional Chinese medicine composition with analgesic effect and preparation method of traditional Chinese medicine composition | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN113058024A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1931286A (en) | Chinese medicine composition for treating lung cancer caused pain | |
| CN102166263B (en) | Compound preparation for treating cervical spondylotic myelopathy and preparation method thereof | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN105617069B (en) | Oral liquid for regulating bipolar affective disorder and preparation method thereof | |
| CN103142928A (en) | Iliacus muscle oral liquid and preparation method thereof | |
| CN103550671A (en) | Application of Zhenlong refreshing pharmaceutical composition in preparation of medicine for treating diabetic peripheral neuropathy | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN103083459B (en) | Traditional Chinese medicinal compound preparation for treating constipation, and preparation method and application thereof | |
| CN101204537B (en) | Chinese traditional medicine composite for reducing spitting, dispelling wind, and relieving convulsion and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ren Wei Inventor after: Zhang Dan Inventor after: Zhang Heng Inventor after: Zhang Ge Inventor before: Sun Zhiqiang |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170821 Address after: 138000 No. 255, Songyuan Road, Songyuan economic and Technological Development Zone, Jilin Patentee after: Jilin century Hank Pharmaceutical Co., Ltd. Address before: 250031, unit 5, building 1, central garden, 17 West Industrial and commercial road, Tianqiao District, Shandong, Ji'nan, 402 Patentee before: Sun Zhiqiang |
|
| TR01 | Transfer of patent right |